What Are PBMCs? Composition, Isolation, and Why Source Quality Matters
Lab Director · OrganaBio · June 2026
What PBMCs are and what they contain
Peripheral blood mononuclear cells (PBMCs) are the fraction of blood cells characterized by a single, round nucleus. The term refers to a collection of different cell types isolated together, not a single cell type. When someone says “we ordered PBMCs,” they mean a mixed population of immune cells separated from red blood cells, platelets, and granulocytes.
The major cell types in a PBMC preparation from a healthy donor:
| Cell Type | Typical Frequency in PBMCs | Function |
|---|---|---|
| T cells (CD3+) | 65–85% | Adaptive immunity; CAR-T starting material |
| CD4+ T cells | 40–60% of T cells | Helper T cells, cytokine production |
| CD8+ T cells | 20–35% of T cells | Cytotoxic T cells, direct killing |
| NK cells (CD56+CD3-) | 5–15% | Innate immunity; CAR-NK starting material |
| B cells (CD19+) | 5–15% | Antibody production, antigen presentation |
| Monocytes (CD14+) | 5–15% | Phagocytosis, cytokine secretion, macrophage precursors |
These ranges are approximate. Actual frequencies vary substantially by donor — which is why immunophenotype data matters when selecting donors for specific applications.
How PBMCs are isolated
The standard isolation method is density gradient centrifugation, most commonly using Ficoll or equivalent density media. The principle: blood components separate by density when centrifuged. PBMCs settle at the interface between the density medium and the plasma layer; red blood cells and granulocytes pellet to the bottom.
The key process variables that affect PBMC quality:
- Time from collection to processing: Longer hold times degrade viability and subset ratios. OrganaBio processes leukopaks within 30 minutes of receipt (receipt to first spin). Processing delays of more than 8 hours can meaningfully affect monocyte and NK cell function.
- Temperature during transport: PBMCs should be transported at room temperature (18–25°C). Cold temperatures can cause monocyte aggregation; elevated temperatures accelerate cell death.
- Centrifugation parameters: Speed, acceleration, and deceleration settings affect the cleanness of the interface and granulocyte contamination in the final prep. Granulocyte contamination greater than 5% reduces PBMC preparation quality for most functional assays.
PBMC yield from a leukopak
A standard full leukopak contains 10 billion or more total white blood cells. PBMC recovery from a leukopak using optimized density gradient separation is typically 70–85% or higher — meaning 7–8.5 billion or more PBMCs from a single collection. OrganaBio achieves greater than 85% PBMC yield with the 30-minute receipt-to-first-spin processing protocol used across all leukopak products.
For comparison, a single unit of whole blood yields approximately 100–300 million PBMCs — roughly 30–100x fewer cells than a leukopak from the same donor.
Fresh vs. cryopreserved PBMCs
Both formats have appropriate use cases. The choice depends on your assay requirements and workflow logistics, not on one format being universally better.
| Consideration | Fresh PBMCs | Cryopreserved PBMCs |
|---|---|---|
| Cell viability on receipt | Typically >95% | >90% post-thaw (optimized cryo) |
| Functional status | Fully active | Some activation upon thaw; rest period recommended |
| Best for | Same-day functional assays, proliferation, cytokine secretion | Batched studies, longitudinal same-donor experiments, scheduled assays |
| Logistics | Must process same day; coordination required | Thaw and use on your schedule |
| Donor recallability | New collection required each time | Multiple vials from one collection available |
What donor data to look for
The value of PBMC characterization data depends on your application. Here is what matters at different levels:
Minimum for most research applications:
- Donor age, sex, race/ethnicity
- CMV serostatus (CMV+ and CMV- donors have measurably different NK and T cell repertoires)
- Basic infectious disease screen (HBV, HCV, HIV, syphilis at minimum)
- Cell count and viability at release
For cell therapy and immunotherapy applications:
- HLA typing — 6-gene NGS HLA (HLA-A, B, C, DR, DQ, DP) for allogeneic program donor selection
- Immunophenotype panel — T/B/NK/monocyte subset frequencies and activation markers
- Donor health history and medication history
- Option to recall the same donor for subsequent collections
PBMCs as starting material for cell therapies
For autologous T cell therapies (patient-derived CAR-T), the starting material is the patient’s own apheresis product. For allogeneic programs using healthy donor cells — allogeneic CAR-T, CAR-NK, and TCR-T programs — PBMCs from a characterized, recallable donor pool are the standard starting material.
The practical criteria for allogeneic starting material:
- Consistent T or NK cell frequency to ensure predictable cell dose
- HLA typing for donor selection and product matching
- Absence of immune activation markers that could reduce T cell expansion potential
- The ability to reorder from the same donor for longitudinal process runs
OrganaBio’s leukopak-derived PBMCs include HLA typing, immunophenotype characterization, and donor recallability as standard features for cell therapy research applications.
Quality signals that indicate a reliable PBMC supplier
- Published or available processing time from collection to first spin (shorter is better)
- Granulocyte contamination rate specified on CoA (well-characterized preps target <5%)
- Immunophenotype data with your order, not just cell count and viability
- Donor recallability for longitudinal work
- Clear RUO designation with a documented GMP path if your program will advance
- Chain-of-custody documentation from donor apheresis to final product
